TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26727655

Group type: EXPERIMENTAL
Intervention: Tocilizumab IV 8 mg/kg every 4 weeks over 31 min
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard 60-min infusions of Tocilizumab IV 8 mg/kg every 4 weeks
Number of subjects: 47
Study: 24184245

Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 219

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 219

Group type: COMPARATOR
Intervention: Hypertensive heart disease patients
Number of subjects: 219
Study: 22507330

Group type: EXPERIMENTAL
Intervention: Allergen exposure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diluent exposure
Number of subjects: 10
Study: 19850848

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Dorzolamide
Number of subjects: 140
Study: 18047457

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program (6 exercises, 3 times per week for 12 weeks, with increasing resistance)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 15612979

Group type: EXPERIMENTAL
Intervention: SRL-ST (sirolimus-steroid regimen without cyclosporine)
Number of subjects: 430

Group type: COMPARATOR
Intervention: SRL-CsA-ST (sirolimus-cyclosporine-steroid regimen)
Number of subjects: 430
Study: 12211647

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (folic acid 5 mg, pyridoxine 40 mg, cyanocobalamin 1 mg once daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no vitamin supplementation)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 21
Study: 10798173

Group type: EXPERIMENTAL
Intervention: Care provided in the admitting and emergency unit
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Care for patients with social problems
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Care for patients with acute problems
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Placement in specialty services
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lack of beds
Number of subjects: 100
Study: 7595106

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment including manipulation
Number of subjects: 59
Study: 1968178

Group type: EXPERIMENTAL
Intervention: Self-inflation of the cuff
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wearing the inflated cuff
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cuff inflation
Number of subjects: 17
Study: 98802

Group type: EXPERIMENTAL
Intervention: Cigarettes of different lengths (whole, half, quarter, eighth)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarettes delivering 0.2 mg nicotine/cigarette
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarettes delivering 2.0 mg nicotine/cigarette
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quarter length cigarettes
Number of subjects: 0
Study: 28538605

Group type: EXPERIMENTAL
Intervention: HEADS-ED tool
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: HEADS-ED score >= 8 and suicidality of 2
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Agreement on needs requiring action
Number of subjects: 639
Study: 31162549

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 12.5 mg
Number of subjects: 40
Study: 25385202

Group type: EXPERIMENTAL
Intervention: Event-based interview
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Frequency-based interview
Number of subjects: 1728

Group type: COMPARATOR
Intervention: No interview
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Evidence-based risk-reduction session
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Standard of care risk-reduction session
Number of subjects: 1728
Study: 24369076

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 146
Study: 21795443

Group type: EXPERIMENTAL
Intervention: BOLUS (25-g dose of whey protein)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PULSE (ten 2.5-g drinks every 20 min of whey protein)
Number of subjects: 8
Study: 19855332

Group type: EXPERIMENTAL
Intervention: Whole body vibration at 50 Hz
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whole body vibration at 20 Hz
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whole body vibration at 35 Hz
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 16
Study: 16942827

Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: EasyTube
Number of subjects: 26

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 26
Study: 12760903

Group type: EXPERIMENTAL
Intervention: Duodenal infusion of 0.1 N hydrochloric acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Duodenal infusion of saline
Number of subjects: 12
Study: 11759464

Group type: EXPERIMENTAL
Intervention: Invitation and offer of payment for contact
Number of subjects: 200

Group type: COMPARATOR
Intervention: No invitation and offer of payment for contact
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Discharge summary distribution
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: General practitioners' contact with hospitals
Number of subjects: 200
Study: 9284426

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 8498759

Group type: EXPERIMENTAL
Intervention: 50 mg methadone
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: 20 mg methadone
Number of subjects: 247

Group type: COMPARATOR
Intervention: 0 mg methadone (placebo)
Number of subjects: 247
Study: 3561160

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg, iv.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 0
Study: 31046757

Group type: EXPERIMENTAL
Intervention: Internship only (I-Group, n=10)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Course only (C-Group, n=21)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Course and internship (CI-Group, n=13)
Number of subjects: 44
Study: 28624123

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 140

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 140
Study: 24729068

Group type: EXPERIMENTAL
Intervention: Driven exercise (DE) in adolescents with anorexia nervosa (AN)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Driven exercise (DE) in adolescents with bulimia nervosa (BN)
Number of subjects: 201
Study: 23391031

Group type: EXPERIMENTAL
Intervention: Roth‐811 sealer
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH‐26 sealer
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Guttaflow sealer
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epiphany SE sealer
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (debrided only)
Number of subjects: 80
Study: 21235477

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with D. pteronyssinus extract
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 18155056

Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia (2 mg morphine in 15 mL of 1% lidocaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal saline in 15 mL)
Number of subjects: 40
Study: 16564436

Group type: EXPERIMENTAL
Intervention: Imaginal reliving in cognitive therapy for PTSD
Number of subjects: 44
Study: 15260199

Group type: EXPERIMENTAL
Intervention: Spatially organized mental map
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temporally organized mental map
Number of subjects: 0
Study: 11197521

Group type: EXPERIMENTAL
Intervention: Various treatments completed by women
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Long-term/recurrent pain incidence
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Shoulder/arm or lower back pain
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Emotional/affective pain effects
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Limitations in daily occupations
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Gender differences in pain prevalence
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Pain variables, daily occupations, sick-leave, work variables
Number of subjects: 10000
Study: 9088300

Group type: EXPERIMENTAL
Intervention: Labored breathing for 1 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labored breathing for 30 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labored breathing for twice 30 min (with a 30‐min interval in between)
Number of subjects: 0
Study: 8392957

Group type: EXPERIMENTAL
Intervention: Ribavirin (0.8-1.0 g daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Interferon beta (3 MU three times weekly)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of ribavirin and interferon beta
Number of subjects: 27
Study: 3486641

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerosis
Number of subjects: 71

Group type: COMPARATOR
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 71
Study: 30932360

Group type: EXPERIMENTAL
Intervention: Arthroscopic Partial Meniscectomy (APM)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 351
Study: 30091688

Group type: EXPERIMENTAL
Intervention: ERSAE‐Stress‐Prosocial (ESPS) intervention
Number of subjects: 183

Group type: COMPARATOR
Intervention: Social Study curriculum (SS) active control group
Number of subjects: 183
Study: 27198539

Group type: EXPERIMENTAL
Intervention: Monolithic zirconia crowns
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contralateral natural antagonists (control teeth)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 20
Study: 24469600

Group type: EXPERIMENTAL
Intervention: Amisulpride (50 mg) with Korean traditional food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amisulpride (50 mg) under fasting state
Number of subjects: 0
Study: 22241786

Group type: EXPERIMENTAL
Intervention: Oral clarithromycin 500 mg/bid for 2 weeks and then 250 mg/d for 6 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topical mometasone furoate 200 mcg/d for 8 weeks added to clarithromycin regimen
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 32
Study: 21084905

Group type: EXPERIMENTAL
Intervention: 64-multidetector-row computed tomography with a bolus-tracking program, scan delay of 10 to 19 seconds
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5-second arterial phase
Number of subjects: 120

Group type: COMPARATOR
Intervention: 15-second arterial phase
Number of subjects: 120
Study: 19055205

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 678

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study: 15878583

Group type: EXPERIMENTAL
Intervention: MSA-P
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Parkinson's disease
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study: 12789263

Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: vinorelbine/cisplatin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin
Number of subjects: 75
Study: 11393462

Group type: EXPERIMENTAL
Intervention: Instructions to exaggerate problems
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Instructions to feign a disorder
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Instructions to feign global psychological disturbance
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (standard instructions)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dissimulation Scale (Ds2)
Number of subjects: 118
Study: 9235556

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7962428

Group type: EXPERIMENTAL
Intervention: Infertile women (unexplained infertility)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fertile women (control group)
Number of subjects: 15
Study: 3653498

Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mg three times a day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg three times a day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 29310868

Group type: EXPERIMENTAL
Intervention: High-velocity nasal insufflation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Noninvasive positive-pressure ventilation
Number of subjects: 204
Study: 27687359

Group type: COMPARATOR
Intervention: Saline (placebo, group C)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Meperidine 0.4mg/kg (group Me)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25mg/kg plus midazolam 37.5μg/kg (group KMi)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Meperidine 0.2mg/kg plus dexamethasone 0.1mg/kg (group MeD)
Number of subjects: 200
Study: 25558561

Group type: EXPERIMENTAL
Intervention: Multiple dilator technique (Group I)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single dilator technique (Group II)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Forceps dilator technique (Group III)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Twist dilator technique (Group IV)
Number of subjects: 16
Study: 22399275

Group type: EXPERIMENTAL
Intervention: 0.8 g CMC-001
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.4 g CMC-001
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.2 g CMC-001
Number of subjects: 32
Study: 20736989

Group type: EXPERIMENTAL
Intervention: Scopolamine (4 μg/kg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 18272538

Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) with external liaisons (liaison schools, LS)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) with internal champions (champion schools, CS)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 515
Study: 16501947

Group type: EXPERIMENTAL
Intervention: Volume-controlled SIMV
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pressure-controlled SIMV
Number of subjects: 15
Study: 12520624

Group type: EXPERIMENTAL
Intervention: Repaglinide 0.5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Repaglinide 1.0 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Repaglinide 2.0 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study: 11349506

Group type: EXPERIMENTAL
Intervention: Enalapril (for normotensive patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (for normotensive patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enalapril (for hypertensive patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acebutolol (for hypertensive patients)
Number of subjects: 100
Study: 8861673

Group type: EXPERIMENTAL
Intervention: Mild hypoxia (HYP) during exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxia (NORM) during exercise
Number of subjects: 14
Study: 1519617

Group type: EXPERIMENTAL
Intervention: Solvent-exposed workers
Number of subjects: 234

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 234
Study: 30044209

Group type: EXPERIMENTAL
Intervention: Family-led rehabilitation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study: 28899680

Group type: EXPERIMENTAL
Intervention: Nutritive sweetener (sucrose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low-calorie sweetener (sucralose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sucralose in solid form
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sucralose and sucrose exposure
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Solid food form
Number of subjects: 64

Group type: COMPARATOR
Intervention: Learning effect
Number of subjects: 64
Study: 25863562

Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3 (four doses of 2.5 mg at weeks 0, 2, 4, and 6)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3 and Placebo
Number of subjects: 247
Study: 24618443

Group type: EXPERIMENTAL
Intervention: Oral pancreatic enzyme supplementation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 22811032

Group type: EXPERIMENTAL
Intervention: Moderate‐intensity exercise training and dietary modification (3 d·wk for up to 55 min per session at 50%‐60% V˙O2peak) for 48 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care (standard of care, instructed not to start a structured exercise program)
Number of subjects: 21
Study: 21091294

Group type: EXPERIMENTAL
Intervention: Trataka (yogic visual concentration practice)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 30
Study: 17473086

Group type: EXPERIMENTAL
Intervention: Condition A (standard serving: 1 large serving at a single time point)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Condition B (portioning: 4 smaller servings presented at a single time point)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Condition C (portioning and eating rate: 4 smaller servings presented at 15-minute intervals)
Number of subjects: 18
Study: 15868655

Group type: EXPERIMENTAL
Intervention: D-003 5 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: D-003 10 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12117626

Group type: EXPERIMENTAL
Intervention: Clinical sample
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Clinical variables (severity of depression, younger age, personality symptoms)
Number of subjects: 260
Study: 9585778

Group type: EXPERIMENTAL
Intervention: Dopamine 2.5 mcg/kg beginning 1 hour before arteriography and continuing for 12 hours
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 55
Study: 7639166

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 49

Group type: COMPARATOR
Intervention: Right heart catheterization
Number of subjects: 49
Study: 11534531

Group type: EXPERIMENTAL
Intervention: β-blockade therapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 662085

Group type: EXPERIMENTAL
Intervention: Amipaque 280 mg I/ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isopaque Cerebral 280 mg I/ml
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amipaque 280 mg I/ml (selective external carotid injection)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isopaque (selective external carotid injection)
Number of subjects: 20
Study: 31420389

Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (no compression)
Number of subjects: 162
Study: 29072432

Group type: EXPERIMENTAL
Intervention: 7-day moxifloxacin-dexlansoprazole based triple therapy with probiotic
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 14-day moxifloxacin-dexlansoprazole based triple therapy with probiotic
Number of subjects: 108

Group type: COMPARATOR
Intervention: 7-day moxifloxacin-dexlansoprazole based triple therapy with placebo
Number of subjects: 108

Group type: COMPARATOR
Intervention: 14-day moxifloxacin-dexlansoprazole based triple therapy with placebo
Number of subjects: 108
Study: 25735205

Group type: EXPERIMENTAL
Intervention: Original digitally recorded speech tokens
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Digitally processed speech tokens emphasizing transient components
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Digitally processed speech tokens emphasizing quasi-steady-state components
Number of subjects: 10
Study: 22819747

Group type: EXPERIMENTAL
Intervention: Serious gaming (active distraction)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lollipops (passive distraction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22136848

Group type: EXPERIMENTAL
Intervention: TSH suppressive therapy (group A)
Number of subjects: 271

Group type: COMPARATOR
Intervention: No therapy (group B)
Number of subjects: 271
Study: 19369462

Group type: EXPERIMENTAL
Intervention: Adalimumab plus MTX
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 678

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 678
Study: 16443858

Group type: EXPERIMENTAL
Intervention: nateglinide 30 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: glibenclamide 1.25 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 15322439

Group type: EXPERIMENTAL
Intervention: Neurophysiology education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Back anatomy and physiology education (Control)
Number of subjects: 0
Study: 11029017

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg with each meal, three times per day for 2.5 days)
Number of subjects: 22
Study: 9071623

Group type: EXPERIMENTAL
Intervention: 400 mg single dose of ketoconazole (Regimen A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 200 mg daily dose of ketoconazole for 10 days (Regimen B)
Number of subjects: 120
Study: 7871052

Group type: EXPERIMENTAL
Intervention: Arecoline (low dose intravenous infusion for up to 2 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Arecoline (blinded, placebo-controlled, individualized optimal dosing for 5 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (during blinded, placebo-controlled phase)
Number of subjects: 9
Study: 3518547

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (3 X 200 mg tablets daily with meals)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (3 tablets daily)
Number of subjects: 118
Study: 30206267

Group type: EXPERIMENTAL
Intervention: 2-g oral TXA 2 hours preoperatively
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 20-mg/kg IV TXA 5 minutes prior to incision
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 2-g IA TXA
Number of subjects: 180